Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon (MEQ00063)

May 3, 2022 updated by: Sanofi Pasteur, a Sanofi Company

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Potential Pilgrims Aged 56 Years and Older

The primary objectives of this study are:

  • To describe the antibody response to meningococcal serogroups A, C, W, and Y measured by serum bactericidal assay using baby rabbit complement (rSBA) before and after a single dose of MenACYW conjugate vaccine
  • To describe the antibody response to meningococcal serogroups A, C, W, and Y measured by serum bactericidal assay using human complement (hSBA) before and after a single dose of MenACYW conjugate vaccine
  • To describe the antibody responses against tetanus toxoid at baseline and after a single dose of MenACYW conjugate vaccine
  • To describe the safety profile of a single dose of MenACYW conjugate vaccine

Study Overview

Detailed Description

Study duration per participant is approximately 30 days including: 1 day of screening and vaccination, a phone call and a safety follow up/end of study visit at Day 8 and Day 30 after vaccine administration, respectively.

Study Type

Interventional

Enrollment (Actual)

260

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beirut, Lebanon
        • Investigational site number 4220001
      • Ankara, Turkey, 06590
        • Investigational site number 7920002
      • Ankara, Turkey, 06800
        • Investigational Site Number 7920001

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

56 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion criteria :

  • Aged ≥ 56 years on the day of inclusion
  • Informed consent form has been signed and dated
  • Able to attend all scheduled visits and to comply with all trial procedures
  • Intending to go on a Hajj or Umrah pilgrimage (but not within the next 10 to 12 months after vaccination)

Exclusion criteria:

  • Participant is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile).
  • Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine prior to Visit 2 except for influenza vaccination, which may be received at least 2 weeks before or after study vaccine. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
  • Any previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, B, C, W, or Y).
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
  • At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia).
  • Known systemic hypersensitivity to any of the vaccine components, or history of a lifethreatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances .
  • Personal history of Guillain-Barre syndrome (GBS).
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within at least 10 years of the proposed study vaccination.
  • Verbal report thrombocytopenia, contraindicating intramuscular vaccination, in the Investigator's opinion.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Current alcohol abuse or drug addiction.
  • Chronic illness (eg, human immunodeficiency virus [HIV], hepatitis B, hepatitis C) that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
  • Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0 C). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: MenACYW conjugate vaccine
MenACYW conjugate single injection at Day 0
Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Other Names:
  • MenQuadfi®

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Antibody titers ≥ 1:8 against meningococcal serogroups A, C, Y, and W
Time Frame: Day 30 (post-vaccination)
Percentage of participants with antibody titers greater than or equal to (≥) 1:8 against meningococcal serogroups A, C, Y, and W as measured by rSBA
Day 30 (post-vaccination)
Antibody titers against meningococcal serogroups A, C, Y, and W (rSBA assessment)
Time Frame: Day 30 (post-vaccination)
Antibodies titers measured by rSBA and expressed as, but not limited to, Geometric Mean Titers (GMTs)
Day 30 (post-vaccination)
Antibody titers against meningococcal serogroups A, C, Y, and W (hSBA assessment)
Time Frame: Day 30 (post-vaccination)
Antibodies titers measured by hSBA and expressed as, but not limited to, GMTs
Day 30 (post-vaccination)
Antibody concentrations to tetanus toxoid
Time Frame: Day 0 (pre-vaccination) and Day 30 (postvaccination)
Geometric Mean Concentrations (GMCs) of antibodies against tetanus toxoid
Day 0 (pre-vaccination) and Day 30 (postvaccination)
Number of participants achieving seroprotective levels
Time Frame: Day 0 (pre-vaccination) and Day 30 (postvaccination)
Seroprotective levels defined as antibody titers ≥ 0.01 International Units (IU) / milliliters (mL) of antibody concentrations to tetanus toxoid
Day 0 (pre-vaccination) and Day 30 (postvaccination)
Number of participants reporting unsolicited systemic adverse events (AEs)
Time Frame: Within 30 minutes post-vaccination
Unsolicited systemic AEs reported in the 30 minutes after each vaccination
Within 30 minutes post-vaccination
Number of participants reporting solicited injection site reactions and systemic reactions
Time Frame: Within 7 days post-vaccination
Solicited (prelisted in the subject's diary card and electronic case report book [CRB]) injection site and systemic reactions occurring up to 7 days after vaccination Injection site reactions: pain, erythema and swelling Systemic reactions: fever, headache, malaise, myalgia
Within 7 days post-vaccination
Number of participants reporting unsolicited non-serious AEs
Time Frame: Within 30 days post-vaccination
Unsolicited AEs (observed AE that does not fulfill the conditions prelisted in the CRB) includes both serious (SAEs) and non-serious unsolicited AEs
Within 30 days post-vaccination
Number of participants reporting serious adverse events (SAEs)
Time Frame: Up to Day 30 (post-vaccination)
SAEs (including adverse events of special interest [AESIs]) reported throughout the study
Up to Day 30 (post-vaccination)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 8, 2019

Primary Completion (ACTUAL)

March 17, 2022

Study Completion (ACTUAL)

March 17, 2022

Study Registration Dates

First Submitted

March 8, 2019

First Submitted That Met QC Criteria

March 8, 2019

First Posted (ACTUAL)

March 11, 2019

Study Record Updates

Last Update Posted (ACTUAL)

May 9, 2022

Last Update Submitted That Met QC Criteria

May 3, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteers (Meningococcal Infection)

Clinical Trials on Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine

3
Subscribe